Monoclonal antibodies against the C-terminal peptide of human tissue factor for studies of the cytoplasmic domain

Steven D Carson, S. C. Yoder

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The carboxyl-terminal cytoplasmic domain of human tissue factor (the essential cofactor for coagulation factor VII) is a prospective regulatory domain through which viable cells may control the expression of tissue factor activity. Furthermore, this domain is subject to post-translational modifications of as yet unknown functional significance. Hybridomas producing antibodies against the C-terminal domain of tissue factor were obtained using splenocytes harvested from mice immunized with a synthetic peptide corresponding to the nine terminal residues of the protein sequence. These antibodies, C28 1.1 and C28 2.1, react with purified placental tissue factor, but not with a recombinant soluble tissue factor lacking the cytoplasmic and membrane-spanning domains. This confirms that tissue factor from biological membranes contains the entire cytoplasmic domain predicted from the cDNA sequence, and provides a mechanism to determine whether tissue factor used experimentally retains this proteolytically sensitive epitope. The antibodies have been employed to demonstrate selective proteolytic removal of the carboxyl-terminal peptide from tissue factor. Limited experiments indicate that they will be useful for characterizing the distribution of vesicles with regard to the possible orientations of tissue factor on their surface.

Original languageEnglish (US)
Pages (from-to)779-787
Number of pages9
JournalBlood Coagulation and Fibrinolysis
Volume3
Issue number6
StatePublished - Dec 1 1992

Fingerprint

Thromboplastin
Monoclonal Antibodies
Peptides
Antibodies
Factor VII
Hybridomas
Post Translational Protein Processing
Epitopes
Complementary DNA
Cell Membrane
Membranes

ASJC Scopus subject areas

  • Hematology

Cite this

Monoclonal antibodies against the C-terminal peptide of human tissue factor for studies of the cytoplasmic domain. / Carson, Steven D; Yoder, S. C.

In: Blood Coagulation and Fibrinolysis, Vol. 3, No. 6, 01.12.1992, p. 779-787.

Research output: Contribution to journalArticle

@article{a2a594d356bc4dfaa63342c29455b7ba,
title = "Monoclonal antibodies against the C-terminal peptide of human tissue factor for studies of the cytoplasmic domain",
abstract = "The carboxyl-terminal cytoplasmic domain of human tissue factor (the essential cofactor for coagulation factor VII) is a prospective regulatory domain through which viable cells may control the expression of tissue factor activity. Furthermore, this domain is subject to post-translational modifications of as yet unknown functional significance. Hybridomas producing antibodies against the C-terminal domain of tissue factor were obtained using splenocytes harvested from mice immunized with a synthetic peptide corresponding to the nine terminal residues of the protein sequence. These antibodies, C28 1.1 and C28 2.1, react with purified placental tissue factor, but not with a recombinant soluble tissue factor lacking the cytoplasmic and membrane-spanning domains. This confirms that tissue factor from biological membranes contains the entire cytoplasmic domain predicted from the cDNA sequence, and provides a mechanism to determine whether tissue factor used experimentally retains this proteolytically sensitive epitope. The antibodies have been employed to demonstrate selective proteolytic removal of the carboxyl-terminal peptide from tissue factor. Limited experiments indicate that they will be useful for characterizing the distribution of vesicles with regard to the possible orientations of tissue factor on their surface.",
author = "Carson, {Steven D} and Yoder, {S. C.}",
year = "1992",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "779--787",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Monoclonal antibodies against the C-terminal peptide of human tissue factor for studies of the cytoplasmic domain

AU - Carson, Steven D

AU - Yoder, S. C.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - The carboxyl-terminal cytoplasmic domain of human tissue factor (the essential cofactor for coagulation factor VII) is a prospective regulatory domain through which viable cells may control the expression of tissue factor activity. Furthermore, this domain is subject to post-translational modifications of as yet unknown functional significance. Hybridomas producing antibodies against the C-terminal domain of tissue factor were obtained using splenocytes harvested from mice immunized with a synthetic peptide corresponding to the nine terminal residues of the protein sequence. These antibodies, C28 1.1 and C28 2.1, react with purified placental tissue factor, but not with a recombinant soluble tissue factor lacking the cytoplasmic and membrane-spanning domains. This confirms that tissue factor from biological membranes contains the entire cytoplasmic domain predicted from the cDNA sequence, and provides a mechanism to determine whether tissue factor used experimentally retains this proteolytically sensitive epitope. The antibodies have been employed to demonstrate selective proteolytic removal of the carboxyl-terminal peptide from tissue factor. Limited experiments indicate that they will be useful for characterizing the distribution of vesicles with regard to the possible orientations of tissue factor on their surface.

AB - The carboxyl-terminal cytoplasmic domain of human tissue factor (the essential cofactor for coagulation factor VII) is a prospective regulatory domain through which viable cells may control the expression of tissue factor activity. Furthermore, this domain is subject to post-translational modifications of as yet unknown functional significance. Hybridomas producing antibodies against the C-terminal domain of tissue factor were obtained using splenocytes harvested from mice immunized with a synthetic peptide corresponding to the nine terminal residues of the protein sequence. These antibodies, C28 1.1 and C28 2.1, react with purified placental tissue factor, but not with a recombinant soluble tissue factor lacking the cytoplasmic and membrane-spanning domains. This confirms that tissue factor from biological membranes contains the entire cytoplasmic domain predicted from the cDNA sequence, and provides a mechanism to determine whether tissue factor used experimentally retains this proteolytically sensitive epitope. The antibodies have been employed to demonstrate selective proteolytic removal of the carboxyl-terminal peptide from tissue factor. Limited experiments indicate that they will be useful for characterizing the distribution of vesicles with regard to the possible orientations of tissue factor on their surface.

UR - http://www.scopus.com/inward/record.url?scp=0027085860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027085860&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 779

EP - 787

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 6

ER -